433 related articles for article (PubMed ID: 24452484)
1. Efficacy and safety of secukinumab in chronic plaque psoriasis and psoriatic arthritis therapy.
Gisondi P; Dalle Vedove C; Girolomoni G
Dermatol Ther (Heidelb); 2014 Jun; 4(1):1-9. PubMed ID: 24452484
[TBL] [Abstract][Full Text] [Related]
2. Psoriasis: rationale for targeting interleukin-17.
Girolomoni G; Mrowietz U; Paul C
Br J Dermatol; 2012 Oct; 167(4):717-24. PubMed ID: 22716185
[TBL] [Abstract][Full Text] [Related]
3. Targeting of interleukin-17 in the treatment of psoriasis.
Lønnberg AS; Zachariae C; Skov L
Clin Cosmet Investig Dermatol; 2014; 7():251-9. PubMed ID: 25246805
[TBL] [Abstract][Full Text] [Related]
4. Interleukin-17A: a unique pathway in immune-mediated diseases: psoriasis, psoriatic arthritis and rheumatoid arthritis.
Kirkham BW; Kavanaugh A; Reich K
Immunology; 2014 Feb; 141(2):133-42. PubMed ID: 23819583
[TBL] [Abstract][Full Text] [Related]
5. IL-17A inhibition by secukinumab induces early clinical, histopathologic, and molecular resolution of psoriasis.
Krueger JG; Wharton KA; Schlitt T; Suprun M; Torene RI; Jiang X; Wang CQ; Fuentes-Duculan J; Hartmann N; Peters T; Koroleva I; Hillenbrand R; Letzkus M; Yu X; Li Y; Glueck A; Hasselberg A; Flannery B; Suárez-Fariñas M; Hueber W
J Allergy Clin Immunol; 2019 Sep; 144(3):750-763. PubMed ID: 31129129
[TBL] [Abstract][Full Text] [Related]
6. Interleukin-17 and innate immunity in infections and chronic inflammation.
Isailovic N; Daigo K; Mantovani A; Selmi C
J Autoimmun; 2015 Jun; 60():1-11. PubMed ID: 25998834
[TBL] [Abstract][Full Text] [Related]
7. Anti IL-17 in psoriasis.
Ly K; Smith MP; Thibodeaux Q; Reddy V; Liao W; Bhutani T
Expert Rev Clin Immunol; 2019 Nov; 15(11):1185-1194. PubMed ID: 31603358
[No Abstract] [Full Text] [Related]
8. Effect of IL-17A blockade with secukinumab in autoimmune diseases.
Patel DD; Lee DM; Kolbinger F; Antoni C
Ann Rheum Dis; 2013 Apr; 72 Suppl 2():ii116-23. PubMed ID: 23253932
[TBL] [Abstract][Full Text] [Related]
9. The Immunologic Role of IL-17 in Psoriasis and Psoriatic Arthritis Pathogenesis.
Blauvelt A; Chiricozzi A
Clin Rev Allergy Immunol; 2018 Dec; 55(3):379-390. PubMed ID: 30109481
[TBL] [Abstract][Full Text] [Related]
10. Secukinumab: a review of the anti-IL-17A biologic for the treatment of psoriasis.
Frieder J; Kivelevitch D; Menter A
Ther Adv Chronic Dis; 2018 Jan; 9(1):5-21. PubMed ID: 29344327
[TBL] [Abstract][Full Text] [Related]
11. Interleukin 17A: toward a new understanding of psoriasis pathogenesis.
Lynde CW; Poulin Y; Vender R; Bourcier M; Khalil S
J Am Acad Dermatol; 2014 Jul; 71(1):141-50. PubMed ID: 24655820
[TBL] [Abstract][Full Text] [Related]
12. Clinical and Molecular Effects of Interleukin-17 Pathway Blockade in Psoriasis.
Green L; Weinberg JM; Menter A; Soung J; Lain E; Jacobson A
J Drugs Dermatol; 2020 Feb; 19(2):138-143. PubMed ID: 32129957
[TBL] [Abstract][Full Text] [Related]
13. Brodalumab: the first anti-IL-17 receptor agent for psoriasis.
Puig L
Drugs Today (Barc); 2017 May; 53(5):283-297. PubMed ID: 28650001
[TBL] [Abstract][Full Text] [Related]
14. Secukinumab, a fully human anti-interleukin-17A monoclonal antibody, exhibits low immunogenicity in psoriasis patients treated up to 5 years.
Reich K; Blauvelt A; Armstrong A; Langley RG; de Vera A; Kolbinger F; Spindeldreher S; Ren M; Bruin G
J Eur Acad Dermatol Venereol; 2019 Sep; 33(9):1733-1741. PubMed ID: 31009130
[TBL] [Abstract][Full Text] [Related]
15. Generation and characterization of ixekizumab, a humanized monoclonal antibody that neutralizes interleukin-17A.
Liu L; Lu J; Allan BW; Tang Y; Tetreault J; Chow CK; Barmettler B; Nelson J; Bina H; Huang L; Wroblewski VJ; Kikly K
J Inflamm Res; 2016; 9():39-50. PubMed ID: 27143947
[TBL] [Abstract][Full Text] [Related]
16. IL-17 targeted therapies for psoriasis.
Chiricozzi A; Krueger JG
Expert Opin Investig Drugs; 2013 Aug; 22(8):993-1005. PubMed ID: 23731078
[TBL] [Abstract][Full Text] [Related]
17. IL-17A in Psoriasis and Beyond: Cardiovascular and Metabolic Implications.
von Stebut E; Boehncke WH; Ghoreschi K; Gori T; Kaya Z; Thaci D; Schäffler A
Front Immunol; 2019; 10():3096. PubMed ID: 32010143
[TBL] [Abstract][Full Text] [Related]
18. Spotlight on brodalumab in the treatment of moderate-to-severe plaque psoriasis: design, development, and potential place in therapy.
Roman M; Chiu MW
Drug Des Devel Ther; 2017; 11():2065-2075. PubMed ID: 28744098
[TBL] [Abstract][Full Text] [Related]
19. Anti-interleukin-17 treatment of psoriasis.
Jinna S; Strober B
J Dermatolog Treat; 2016 Aug; 27(4):311-5. PubMed ID: 26943806
[TBL] [Abstract][Full Text] [Related]
20. Interleukin-17 (IL-17) inhibitors in the treatment of plaque psoriasis: a review.
Gooderham M; Posso-De Los Rios CJ; Rubio-Gomez GA; Papp K
Skin Therapy Lett; 2015; 20(1):1-5. PubMed ID: 25807214
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
